Table 1.
Characteristics (%) of the COVID-19 cases and sex and age matched controls, stratified by the follow-up period for monitoring of VE. Percentages have been calculated separately for cases and controls in each period
| Follow-up period, year 2021 | ||||||
|---|---|---|---|---|---|---|
| Period 1, weeks 10–20 (days 71–147) | Period 2, weeks 21–32 (days 148–231) | Period 3, weeks 33–44 (days 232–315) | ||||
| Cases | Controls | Cases | Controls | Cases | Controls | |
| N | 38 223 | 382 230 | 5 875 | 58 750 | 8027 | 80 270 |
| Age | ||||||
| 0–17 | 18.1 | 18.4 | 18.8 | 20.7 | 30.1 | 29.2 |
| 18–39 | 36.8 | 36.5 | 49.4 | 47.5 | 34.9 | 35.8 |
| 40–64 | 38.4 | 38.4 | 28.2 | 28.2 | 28.7 | 28.7 |
| 65 | 6.7 | 6.7 | 3.6 | 3.6 | 6.3 | 6.3 |
| Sex | ||||||
| Females | 49.8 | 49.8 | 50.3 | 50.3 | 52.0 | 52.0 |
| Males | 50.2 | 50.2 | 49.7 | 49.7 | 48.0 | 48.0 |
| Born abroad | 22.3 | 26.0 | 25.0 | 26.0 | 37.6 | 24.4 |
| Civil status | ||||||
| Married | 35.7 | 32.1 | 28.7 | 25.4 | 31.5 | 26.7 |
| Widow/widower | 1.2 | 1.2 | 0.9 | 0.7 | 1.5 | 1.3 |
| Divorced | 8.4 | 9.1 | 6.8 | 6.4 | 8.4 | 7.0 |
| Single | 54.7 | 57.7 | 63.7 | 67.5 | 58.6 | 65.0 |
| Vaccine doses | ||||||
| 0 | 94.7 | 90.9 | 77.9 | 70.2 | 64.0 | 44.0 |
| 1 | 4.4 | 5.7 | 15.9 | 18.1 | 8.9 | 11.4 |
| 2 | 1.0 | 3.4 | 6.2 | 11.7 | 26.9 | 44.4 |
| 3 | 0.2 | 0.1 | ||||
| Vaccine typea | N = 365 | N = 13 123 | N = 366 | N = 6876 | N = 2174 | N = 35 791 |
| Pfizer | 92.3 | 90.3 | 72.1 | 72.5 | 81.0 | 79.1 |
| Moderna | 6.3 | 8.5 | 10.4 | 11.7 | 6.6 | 13.0 |
| AZ | 1.1 | 0.8 | 12.0 | 7.9 | 8.7 | 5.0 |
| Mixed | 0.3 | 0.5 | 5.5 | 7.9 | 3.8 | 2.9 |
| Time since last dosea | ||||||
| 0–3 months | 89.9 | 92.4 | 69.7 | 77.2 | 50.0 | 66.3 |
| 3–6 months | 10.1 | 7.6 | 27.9 | 21.6 | 36.3 | 27.4 |
| ≥6 months | 0.0 | 0.0 | 2.5 | 1.2 | 13.7 | 6.3 |
| Prior SARS-CoV-2 infection | 0.6 | 7.4 | 2.7 | 11.1 | 2.6 | 12.9 |
| Hospitalised | 3.0 | – | 1.9 | – | 3.0 | – |
a
Only persons with at least two doses.